Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. (YMAB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ymab · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Y-mAbs Therapeutics, Inc.You YMAB | $391M | N/A | — | — |
 Big Cypress Acquisition Corp. BCYP | $425M | 12.28x | — | $0.69 |
 Checkpoint Therapeutics, Inc. CKPT | $368M | N/A | — | -$1.42 |
 Climb Bio, Inc. CLYM | $734M | N/A | — | -$0.88 |
 G1 Therapeutics, Inc. GTHX | $378M | N/A | — | -$0.93 |
 iTeos Therapeutics, Inc. ITOS | $449M | N/A | — | -$3.32 |
 Orchard Therapeutics plc ORTX | $380M | N/A | — | -$0.62 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Y-mAbs Therapeutics, Inc. (YMAB) measures how much investors pay for each dollar of the company's trailing earnings. YMAB's current PE ratio of N/A is calculated by dividing its stock price of $8.61 by its TTM earnings per share of —.
Frequently asked questions
YMAB pe ratio · 6 questionsYMAB's current PE ratio is N/A as of 2026-06-09, based on a stock price of $8.61 and TTM EPS of —. Data sourced from Financial Modeling Prep via YMAB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Y-mAbs Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09